BMS cancer drug’s expanded approval gives it an edge over a Gilead cell therapy
A Bristol Myers Squib cancer drug made by engineering a patient’s own immune cells is now approved to treat patients in earlier stages of their disease, a regulatory decision that expands the number of patients that can be reached with this type of personalized cell therapy. The decision could also give BMS an edge over … Read more